$STAB CORRECTION - Statera Biopharma Submits Phase 1 Clinical Trial Protocol to FDA for Investigational Treatment of Long-Haul COVID-19 Statera developing STAT-205 as novel therapy for immune modulation in treating post-acute (long-haul) patients with SARS-CoV-2 (COVID-19)
FORT COLLINS, Colo., March 02, 2022 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Statera Biopharma, Inc. (Nasdaq: STAB), please note an additional sentence has been added to the fifth paragraph. The corrected release follows:
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.